Abstracts Archive - Page 16 of 2616 - ACR Meeting Abstracts

Abstract Number: 0151 • ACR Convergence 2025
Post-COVID Decline in Systemic Lupus Erythematosus Mortality in the United States: A National Analysis from 2014 to 2023
Ghassan Makhoul¹, Aziz-ur-Rahman Khalid², Islam Rajab¹, Hasan Munshi¹, Emmanuel Olumuyide³, MD Walid Akram Hussain¹, Aqsa Sorathia¹, Reshma John¹, Ahmed Huzien¹, ivan Mercado¹, Nargis Mateen⁴ and Robert Lahita², ¹St. Josephs University Medical Center, Paterson, ²St. Josephs University Medical Center, Wayne, NJ, ³Advocate Illinois Masonic Medical Center, Chicago, ⁴St. Josephs University Medical Center, Paterson, NJ
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease with high morbidity and mortality. The impact of the COVID-19 pandemic on SLE-related deaths…
Abstract Number: 0187 • ACR Convergence 2025
Message Testing in Online Recruitment Advertisements for a National Rheumatoid and Psoriatic Arthritis Study
Matthew Kearney¹, Sarah Hopkins Gillespie¹, Stephanie Chen¹, Tyler Cavin², Christine Lindsay³, Christopher Ritchlin⁴, Jennifer Seifert⁵, Susan Goodman⁶, Jessica Fishman¹ and Alexis Ogdie⁷, ¹University of Pennsylvania, Philadelphia, PA, ²University of Rochester, Rochester, NY, ³Self, prosper, TX, ⁴University of Rochester Medical Center, Canandaigua, NY, ⁵University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, ⁶Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁷Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE
Background/Purpose: Study recruitment procedures have increasingly included paid advertisements using social media. However, it is unclear which types of message framing will be the most…
Abstract Number: 0143 • ACR Convergence 2025
High-dimensional Spectral Flow Cytometry Reveals a Unique Distribution of Circulating B Cells in Patients with Antiphospholipid Syndrome
Yuzhou Gan¹, Srilakshmi Yalavarthi², Yiran Shen¹, Cyrus Sarosh³, Xiangjun Liu⁴, Ajay Tambralli¹, Jacqueline Madison¹, Yu (Ray) Zuo¹ and Jason S. Knight¹, ¹University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, ³University of Michigan, Temperance, MI, ⁴Peking University, Beijing, Beijing, China
Background/Purpose: Background: Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by the presence of pathogenic antiphospholipid antibodies (aPL) in the setting of venous or…
Abstract Number: 0138 • ACR Convergence 2025
Evaluating Artificial Intelligence for Diagnosing Antiphospholipid Syndrome in Pulmonary Embolism Case Reports: A Prompt-Based Analysis
Sami Rabah and Xiangyi Kang, Lincoln Medical Center, New York, NY
Background/Purpose: Antiphospholipid syndrome (APS) is a complex autoimmune prothrombotic disorder that can present with venous or arterial thromboses, often masquerading as unprovoked pulmonary embolism (PE).…
Abstract Number: 0194 • ACR Convergence 2025
Evaluation of a Home-based Therapeutics Service: Feasibility, Patient and Caregiver Experience, and Cost
Xiaohui Xin, Andrea Low, Sow Ling Yee, Miao Miao Liu, Christina Tan, Daphne Ng and Siaw Ing Yeo, Singapore General Hospital, Singapore, Singapore
Background/Purpose: The home-based therapeutics service (HTS) by a community nurse is part of an ongoing larger initiative—Community Therapeutics Programme (CTP)—spearheaded by the Rheumatology and Immunology…
Abstract Number: 0158 • ACR Convergence 2025
Association between newer COVID-19 vaccines and COVID-19 related hospitalizations among people with autoimmune rheumatic diseases in the U.S. National COVID Cohort Collaborative (N3C)
Lesley Jackson¹, jerrod anzalone², Rahima Begum³, Fazlur Rahman¹, Namrata Singh⁴, Londyn Robinson⁵, Kaleb Michaud², Kenneth Saag⁶, Jasvinder Singh⁷, Rena Patel¹ and Maria I. ("Maio") Danila⁸, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Nebraska Medical Center, Omaha, NE, ³University of Alabama at Birmingham, Birmingham, ⁴University of Washington, Bellevue, WA, ⁵University of Washington, Seattle, WA, ⁶The University of Alabama at Birmingham, Birmingham, AL, ⁷Baylor College of Medicine, Houston, TX, ⁸University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: People with autoimmune rheumatic diseases (AIRD) are at higher risk for serious complications and poor outcomes from COVID-19 infection. Data is lacking on outcomes…
Abstract Number: 0148 • ACR Convergence 2025
Air Pollution as a Trigger for Flares in Chronic Inflammatory Rheumatic Diseases: a Prospective Single-Center Study in the South of France
Coralie Cruzel¹, antonio Iannelli², Alexandre Armengaud³, Sonia Oppo³, Marie Charlotte Trojani⁴, Stephanie Ferrero⁴, Veronique Breuil⁴, Eric Fontas⁵, Christian Roux⁴ and Clément Viala⁴, ¹². Department of Clinical Research, Cimiez Hospital, CHU Nice, Université Côte d'Azur, Nice, France, France, France, ²³. Centre Hospitalier Universitaire de Nice-Digestive Surgery and Liver Transplantation Unit, Archet ² Hospital, ⁰⁶²⁰² Nice, France., NIce, France, ³¹. University Cote d’Azur, Rheumatology department, CHU Nice, France, Marseille, France, ⁴¹. University Cote d’Azur, Rheumatology department, CHU Nice, France, NIce, France, ⁵². Department of Clinical Research, Cimiez Hospital, CHU Nice, Université Côte d'Azur, Nice, France, NIce, France
Background/Purpose: Rheumatoid arthritis (RA) and spondyloarthritis (SpA), are chronic inflammatory rheumatic diseases. Despite significant advancements in their management through novel therapies, some patients continue to…
Abstract Number: 0140 • ACR Convergence 2025
Outcome Of Patients With Non-Criteria Manifestations Of Primary Antiphospholipid Syndrome Treated With Immunosuppressants -A Single Centre Study
Sindhuja Rajendran¹, ashish mathew², sukesh chandran nair³, john mathew² and ruchika goel², ¹Christian Medical College ,Vellore, Madurai, Tamil Nadu, India, ²Christian Medical college , Vellore , India, Vellore, Tamil Nadu, India, ³Christian,Medical College ,Vellore ,India, Vellore, Tamil Nadu, India
Background/Purpose: Non-criteria manifestations occur in 24% in Primary antiphospholipid syndrome (PAPS) . The efficacy of immunosuppressants in patients with above condition is not certain due…
Abstract Number: 0150 • ACR Convergence 2025
Mortality in Anca-associated Vasculitis
Fabricio Benavides Villanueva¹, Vanesa Calvo-Río², Diana Prieto-Peña³, Monica Renuncio-García⁴, Adrian Martin-Gutierrez⁵, Amparo Sanchez-Lopez⁶, Claudia Poo-fernandez⁷, Clara Escagedo-Cagigas⁸, maria Rodríguez-Vidriales⁸ and Ricardo Blanco², ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Immunopathology Group,Santander, Spain, Santander, Spain, ²Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ⁴Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, ⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, ⁶Division of Dermatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, ⁷Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, ⁸Division of Nephrology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), include Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Eosinophilic Granulomatosis with Polyangiitis (EGPA). Mortality rates are scare,…
Abstract Number: 0188 • ACR Convergence 2025
Investigating Canadians’ information needs related to lupus: A Google Trends analysis of online search query data
Taylor Williamson¹, Emily Shantz¹, Susan Elliott¹, Christine Sperling², Karen H. Costenbader³ and May Choi⁴, ¹University of Waterloo, Waterloo, Canada, ²None, Calgary, Canada, ³Harvard Medical School and Brigham and Women's Hospital, Boston, MA, ⁴University of Calgary, Calgary, AB, Canada
Background/Purpose: A lack of knowledge surrounding SLE has been identified as a main challenge for patients, particularly those seeking a diagnosis or recently diagnosed. Subsequently,…
Abstract Number: 0142 • ACR Convergence 2025
Risk Factors for Antiphospholipid Syndrome-associated Nephropathy: A Retrospective Cohort Analysis
Xiaohan Wei¹, Zhixia Yang², Haoyu Pan², Yuying Fan², Jinyi Qian², Shuyi Yu² and Hui Shi³, ¹Shanghai JiaoTong University, Shanghai, China (People's Republic), ²Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ³Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)
Background/Purpose: To identify independent clinical and laboratory risk factors associated with antiphospholipid syndrome-associated nephropathy (APSN) and highlight the clinical importance of early screening in high-risk…
Abstract Number: 0154 • ACR Convergence 2025
Incidence and Prevalence of Connective Tissue Diseases with Interstitial Lung Disease (CTD-ILD) in the United States
Diana Martins¹, George Mu², Elaine Irving³, Roger A. Levy⁴, Nisha Bhatt⁵ and Keele E. Wurst⁶, ¹GSK, Epidemiology, Toronto, ON, Canada, ²GSK, Statistics, Collegeville, PA, ³GSK, Clinical, Stevenage, United Kingdom, ⁴GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁵GSK, Global Medical Affairs, Collegeville, PA, ⁶GSK, Immunology and Emerging Epidemiology, Durham, NC
Background/Purpose: Despite the high disease burden and reduced quality of life for patients with CTD-ILD, data on its incidence and prevalence – particularly by CTD…
Abstract Number: 0162 • ACR Convergence 2025
Clinical Relevance of Systematic Comorbidity Screening in Autoimmune and Inflammatory Diseases
Martin Michaud, Caroline Arlet, Jean Alain Bournazeau, François de Maupeou, Julie Gaston, Stephanie Mermet, Helene Coulier, Marie Oustalet, Christophe Raspaud, Cédric Maurice, Sophie Recipon, Claire Verplancken, Kim Paricaud and Leonardo Astudillo, Clinique Saint Exupery, TOULOUSE, France
Background/Purpose: Chronic autoimmune and inflammatory diseases are associated with an increased prevalence of various comorbidities, which may impact both prognosis and therapeutic strategies. EULAR recommends…
Abstract Number: 0169 • ACR Convergence 2025
The High Disease Burden of Connective Tissue Disorder-Interstitial Lung Disease in the USA Demonstrates an Unmet Need for Earlier Diagnosis and Treatment
Sally Wetten¹, George Mu², Keele E. Wurst³, Roger A. Levy⁴, Ben Newth⁵, Svetlana I. Nihtyanova⁶ and Elaine Irving⁷, ¹GSK, Epidemiology, Stevenage, United Kingdom, ²GSK, Statistics, Collegeville, PA, ³GSK, Immunology and Emerging Epidemiology, Durham, NC, ⁴GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁵GSK, Specialty Care, Global Medical Affairs, London, United Kingdom, ⁶GSK, Clinical Sciences, Research & Development, London, United Kingdom, ⁷GSK, Clinical, Stevenage, United Kingdom
Background/Purpose: Interstitial lung disease (ILD) is a serious pulmonary manifestation that can occur across all connective tissue disorders (CTD). Aberrant immune-mediated inflammation and fibrosis leads…
Abstract Number: 0177 • ACR Convergence 2025
Artificial intelligence in adult and paediatric rheumatology practice and research: pilot results from an international survey
Ana Isabel Rebollo-Gimenez¹, Saverio La bella², Krystel Aouad³, Latika Gupta⁴, Davide Cangelosi⁵, Thomas Högle⁶, Johannes Knitza⁷, Nicolino Ruperto⁸, Vincenzo Venerito⁹, Abdellah El Maghraoui¹⁰, Alessandra Alongi¹¹, Wilson bautista molano¹², Deniz Bayraktar¹³, Thomas Davergne¹⁴, Dzifa Dey¹⁵, Ihsane Hmamouchi¹⁶, Alison Hoens¹⁷, Linda Li¹⁷, Angela Migowa¹⁸, Erin Treemarcki¹⁹, Nelly Ziade²⁰, Tue Kragstrup²¹ and Diego Benavent²², ¹Department of Rheumatology, Gregorio Marañon University Hospital, Gregorio Marañon Health Research Institute, Madrid, Spain, ²UOC Reumatologia e Malattie Autoinfiammatorie, IRCCS Istituto Giannina Gaslini, Genoa, Italy, ³Department of Rheumatology, Saint George Hospital University Medical Center, Beirut, Lebanon, ⁴School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom, ⁵Unità di Bioinformatica Clinica, Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genoa, Italy, ⁶Department of Rheumatology, University Hospital Lausanne (CHUV) and University of Lausanne, Lausanne, Switzerland, ⁷Institute for Digital Medicine, University Hospital Gießen-Marburg, Philipps University, Marburg, Germany, ⁸Université Milano Bicocca and Fondazione IRCSS S. Gerardo dei Tintori, Monza, Monza and Brianza, Italy, ⁹Univeristy of Bari "Aldo Moro", Italy, Bari, Bari, Italy, ¹⁰Department of Rheumatology, Military Hospital Mohammed V, Rabat, Morocco, ¹¹Università Milano Bicocca, Milano, MILAN, Italy, ¹²University Hospital Fundacion Santa Fe de Bogota, Bogota, Colombia, ¹³Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Izmir Katip Celebi University. Arthritis Research Canada, Vancouver, British Columbia., Izmir, Turkey, ¹⁴Department of rehabilitation.Team METHODS, CRESS UMR ¹¹⁵³ – University of Paris Cité, Paris, France, ¹⁵Rheumatology Unit Department of Medicine and Therapeutics, Korle bu Teaching Hospital, University of Ghana Medical School, Accra, Ghana, ¹⁶Health Sciences Research Center (CReSS).Faculty of Medicine, International University of Rabat, Rabat, Morocco, ¹⁷Department of Physical Therapy, University of British Columbia, Vancouver, BC, Canada, ¹⁸Aga Khan University Medical College East Africa, Nairobi, Kenya, ¹⁹Department of Pediatrics, Division of Pediatric Rheumatology, University of Utah, Salt Lake City, UT, ²⁰Department of Rheumatology, Saint-Joseph University and Hotel-Dieu de France, Beirut, Lebanon, ²¹Department of Biomedicine, Aarhus University & Rheumatology Sector, Medical Diagnostic Center, Silkeborg Regional Hospital, Silkeborg, Aarhus C, Denmark, ²²Hospital Universitari de Bellvitge, Madrid, Spain
Background/Purpose: Artificial intelligence (AI) is transforming rheumatology care, with innovative tools now empowering physicians and health professionals (HPRs). Our survey examines how adult and pediatric…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].